Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 with or without cetrelimab versus intravesical BCG in BCG-naive high-risk non-muscle invasive bladder cancer
NL-OMON59935Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) comparing TAR-200 + cetrelimab, Intravesical BCG and TAR-200 alone (3 arms). Primary endpoint: Event-free survival. Started Oct 2023; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimabbcg vaccinegemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NL-OMON59935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59935.